The current state of proteomics in GI oncology

Ying Lin, William S. Dynan, Jeffrey R Lee, Zhao Hua Zhu, Robert R. Schade

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Proteomics refers to the study of the entire set of proteins in a given cell or tissue. With the extensive development of protein separation, mass spectrometry, and bioinformatics technologies, clinical proteomics has shown its potential as a powerful approach for biomarker discovery, particularly in the area of oncology. More than 130 exploratory studies have defined candidate markers in serum, gastrointestinal (GI) fluids, or cancer tissue. In this article, we introduce the commonly adopted proteomic technologies and describe results of a comprehensive review of studies that have applied these technologies to GI oncology, with a particular emphasis on developments in the last 3 years. We discuss reasons why the more than 130 studies to date have had little discernible clinical impact, and we outline steps that may allow proteomics to realize its promise for early detection of disease, monitoring of disease recurrence, and identification of targets for individualized therapy.

Original languageEnglish (US)
Pages (from-to)431-457
Number of pages27
JournalDigestive Diseases and Sciences
Volume54
Issue number3
DOIs
StatePublished - Mar 1 2009

Fingerprint

Proteomics
Technology
Biomarkers
Computational Biology
Early Diagnosis
Mass Spectrometry
Proteins
Recurrence
Neoplasms
Therapeutics

Keywords

  • Biomarker discovery
  • Clinical proteomics
  • Gastrointestinal oncology
  • Mass spectrometry

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology

Cite this

Lin, Y., Dynan, W. S., Lee, J. R., Zhu, Z. H., & Schade, R. R. (2009). The current state of proteomics in GI oncology. Digestive Diseases and Sciences, 54(3), 431-457. https://doi.org/10.1007/s10620-008-0656-5

The current state of proteomics in GI oncology. / Lin, Ying; Dynan, William S.; Lee, Jeffrey R; Zhu, Zhao Hua; Schade, Robert R.

In: Digestive Diseases and Sciences, Vol. 54, No. 3, 01.03.2009, p. 431-457.

Research output: Contribution to journalReview article

Lin, Y, Dynan, WS, Lee, JR, Zhu, ZH & Schade, RR 2009, 'The current state of proteomics in GI oncology', Digestive Diseases and Sciences, vol. 54, no. 3, pp. 431-457. https://doi.org/10.1007/s10620-008-0656-5
Lin, Ying ; Dynan, William S. ; Lee, Jeffrey R ; Zhu, Zhao Hua ; Schade, Robert R. / The current state of proteomics in GI oncology. In: Digestive Diseases and Sciences. 2009 ; Vol. 54, No. 3. pp. 431-457.
@article{23719bbce5624ab69f58fdbf75e5dd45,
title = "The current state of proteomics in GI oncology",
abstract = "Proteomics refers to the study of the entire set of proteins in a given cell or tissue. With the extensive development of protein separation, mass spectrometry, and bioinformatics technologies, clinical proteomics has shown its potential as a powerful approach for biomarker discovery, particularly in the area of oncology. More than 130 exploratory studies have defined candidate markers in serum, gastrointestinal (GI) fluids, or cancer tissue. In this article, we introduce the commonly adopted proteomic technologies and describe results of a comprehensive review of studies that have applied these technologies to GI oncology, with a particular emphasis on developments in the last 3 years. We discuss reasons why the more than 130 studies to date have had little discernible clinical impact, and we outline steps that may allow proteomics to realize its promise for early detection of disease, monitoring of disease recurrence, and identification of targets for individualized therapy.",
keywords = "Biomarker discovery, Clinical proteomics, Gastrointestinal oncology, Mass spectrometry",
author = "Ying Lin and Dynan, {William S.} and Lee, {Jeffrey R} and Zhu, {Zhao Hua} and Schade, {Robert R.}",
year = "2009",
month = "3",
day = "1",
doi = "10.1007/s10620-008-0656-5",
language = "English (US)",
volume = "54",
pages = "431--457",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - The current state of proteomics in GI oncology

AU - Lin, Ying

AU - Dynan, William S.

AU - Lee, Jeffrey R

AU - Zhu, Zhao Hua

AU - Schade, Robert R.

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Proteomics refers to the study of the entire set of proteins in a given cell or tissue. With the extensive development of protein separation, mass spectrometry, and bioinformatics technologies, clinical proteomics has shown its potential as a powerful approach for biomarker discovery, particularly in the area of oncology. More than 130 exploratory studies have defined candidate markers in serum, gastrointestinal (GI) fluids, or cancer tissue. In this article, we introduce the commonly adopted proteomic technologies and describe results of a comprehensive review of studies that have applied these technologies to GI oncology, with a particular emphasis on developments in the last 3 years. We discuss reasons why the more than 130 studies to date have had little discernible clinical impact, and we outline steps that may allow proteomics to realize its promise for early detection of disease, monitoring of disease recurrence, and identification of targets for individualized therapy.

AB - Proteomics refers to the study of the entire set of proteins in a given cell or tissue. With the extensive development of protein separation, mass spectrometry, and bioinformatics technologies, clinical proteomics has shown its potential as a powerful approach for biomarker discovery, particularly in the area of oncology. More than 130 exploratory studies have defined candidate markers in serum, gastrointestinal (GI) fluids, or cancer tissue. In this article, we introduce the commonly adopted proteomic technologies and describe results of a comprehensive review of studies that have applied these technologies to GI oncology, with a particular emphasis on developments in the last 3 years. We discuss reasons why the more than 130 studies to date have had little discernible clinical impact, and we outline steps that may allow proteomics to realize its promise for early detection of disease, monitoring of disease recurrence, and identification of targets for individualized therapy.

KW - Biomarker discovery

KW - Clinical proteomics

KW - Gastrointestinal oncology

KW - Mass spectrometry

UR - http://www.scopus.com/inward/record.url?scp=59449088564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59449088564&partnerID=8YFLogxK

U2 - 10.1007/s10620-008-0656-5

DO - 10.1007/s10620-008-0656-5

M3 - Review article

C2 - 19104933

AN - SCOPUS:59449088564

VL - 54

SP - 431

EP - 457

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 3

ER -